• Ribonuclease R and circRNA Evidence in Pulpitis

  2026-10-06

  Ribonuclease R provides a topology-aware lens for interpreting circular RNA evidence in pulpitis. This article distinguishes circular RNA enrichment from functional causality and shows how RNase R can strengthen, but not independently prove, mechanistic claims about the circ_0042103/TAF15/NER axis.

• Reserpine Product Overview and Evidence Limits

  2026-10-05

  Reserpine (SKU N1867; CAS 50-55-5) is a supplier-described Rauvolfia-derived natural product with a reported molecular weight of 608.27. The catalog frames it for neurotransmitter depletion research, antihypertensive mechanism studies, and neuropharmacology research, but no matched paper evidence is available here to validate performance, mechanisms, or outcomes.

• Optimized hiPSC Platelet Differentiation: Key Findings

  2026-10-05

  A 2026 study presents an optimized human induced pluripotent stem cell differentiation strategy that improves megakaryocyte and platelet production while reducing reported cost and culture duration. Its evidence supports a promising ex vivo manufacturing concept, but the findings remain limited to in vitro characterization and should not be conflated with clinical transfusion efficacy or cancer-model evidence.

• Reserpine N1867: Product Overview

  2026-10-04

  Reserpine (SKU N1867; CAS 50-55-5) is listed by APExBIO as a Rauvolfia-derived research compound. No matched paper evidence is available, so this overview is limited to supplier-reported identity and conceptual research scope.

• Epacadostat and IDO1: Evidence in Immunometabolism

  2026-10-03

  Epacadostat (INCB024360) is a selective IDO1 inhibitor used to study tryptophan metabolism and immune regulation. This overview compares its mechanistic rationale with evidence from standardized whole-blood immunometabolism research and clinical checkpoint-inhibitor testing, while distinguishing product claims, published findings, interpretation, and important applicability limits.

• Tat, EZH2, and HIV Latency in Astrocytes

  2026-10-02

  The reference study identifies an epigenetic mechanism linking HIV Tat expression to increased H3K27me3 and latent infection in astrocytes. Using reporter viruses, pharmacological EZH2 inhibition, and molecular time-course analysis, the authors show that EZH2–MeCP2-associated chromatin regulation may help determine whether HIV remains transcriptionally silent in this central nervous system cell type.

• EZ Cap™ CBEmax mRNA: Translational Design

  2026-10-01

  Cytosine base editing is moving from an efficiency-first conversation toward a translational framework built on mechanism, control design, and fidelity. This thought-leadership article explains how EZ Cap™ CBEmax mRNA (m1Ψ), SKU R1044, can support disciplined research workflows without confusing product availability with product-specific efficacy or clinical validation.

• Lipo3K Transfection Reagent for ASO Assays

  2026-10-01

  Lipo3K Transfection Reagent provides a practical delivery framework for gene expression studies, RNA interference research, and emerging antisense oligonucleotide assays. This article connects lipid-mediated nucleic acid delivery with the structure–activity lessons of a pH-responsive i-motif ASO study, while separating established product capabilities from questions that still require validation.

• Chronic Cabozantinib Signaling Adaptation in RCC

  2026-09-30

  This study uses quantitative phosphoproteomics to distinguish acute from chronic Cabozantinib adaptation in renal cell carcinoma. It shows that prolonged exposure preserves suppression of activation-loop MET phosphorylation while selectively remodeling adhesion-, stress-, and MAPK/AP-1-associated signaling alongside pattern-specific motility changes.

• Cefotaxime Workflows for Resistance Research

  2026-09-30

  Build reproducible Cefotaxime assays for antimicrobial resistance research, from fresh-solution handling and broth microdilution to plasmid-transfer phenotyping. The workflow connects beta-lactam antibiotic mechanism studies with bacterial infection model design while emphasizing controls, stability, and interpretation limits.

• Reserpine N1867: Practical Lab Workflow

  2026-09-29

  Reserpine N1867 provides a characterized research compound for controlled neurotransmitter depletion research, antihypertensive mechanism studies, and neuropharmacology workflows. This guide addresses identity verification, DMSO stock preparation, storage, and assay QC; the material is for research use only and not for diagnostic or medical applications.

• Reserpine N1867: Practical Lab Workflow

  2026-09-29

  This guide provides a controlled preparation, storage, and QC workflow for Reserpine (SKU N1867) in neurotransmitter depletion research, antihypertensive mechanism studies, and neuropharmacology research. It is intended for research use only and does not establish diagnostic, clinical, therapeutic, veterinary, or hypertension-treatment applications.

• Moesin as a Biomarker of Endothelial Injury

  2026-09-28

  The reference study links elevated circulating moesin with sepsis severity and combines patient, mouse, and endothelial-cell evidence to investigate its mechanistic relevance. Its most important contribution is the integration of biomarker correlations with Rock1/MLC and NF-κB pathway experiments, while also highlighting limits on interpreting moesin as a standalone diagnostic marker.

• Shenqi Fuzheng Injection in Glioma: SRC/PI3K/AKT

  2026-09-28

  This study combined network pharmacology with cell-based assays and a mouse glioma model to investigate Shenqi Fuzheng injection (SFI). Its findings link SFI-associated reductions in glioma cell proliferation and migration to cell-cycle changes and implicate SRC/PI3K/AKT signaling, while leaving the precise molecular targets to be established.

• Lipo3K Transfection Reagent for ccRCC Studies

  2026-09-27

  Build practical gene-modulation experiments around the OTUD3–SLC7A11 pathway and sunitinib resistance in clear cell renal cell carcinoma. Lipo3K supports DNA, siRNA, and combined delivery, with low-toxicity handling that can simplify downstream collection and optimization in challenging cell models.

8524 records 1/569 page Next 12345 下5页 Last page